Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells

Cancer Prevention Research

Volumn 1, Issue 3, 2008, Pages 201-207

  Zhang, Jie ^a   Iwanaga, Kentaro ^a   Choi, Kuicheon C ^a   Wislez, Marie ^b   Raso, Maria Gabriela ^a   Wei, Wei ^a   Wistuba, Ignacio I ^a   Kurie, Jonathan M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIREGULIN; TUMOR MARKER;

ARTICLE; CELL SURVIVAL; DISEASE COURSE; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; LYMPH NODE METASTASIS; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; PROTO ONCOGENE; TISSUE MICROARRAY; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MUTATION; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 61449229208     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0014     Document Type: Article

References (31)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med2004;350: 2129-39.
2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
3. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" andare associatedwith sensitivity of tumors to gefitinib anderlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
4. Ji H, Li D, Chen L, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR- targetedtherapies. Cancer Cell 2006;9:485-95.
5. Politi K, Zakowski MF, Fan PD, SchonfeldEA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006; 20:1496-510.
6. Sato M, Vaughan MB, GirardL, et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 2006;66:2116-28.
7. Amann J, Kalyankrishna S, Massion PP, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005;65:226-35.
8. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib- sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305: 1163-7.
9. Engelman JA, Janne PA, Mermel C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib- sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 2005;102:3788-93.
10. Engelman JA, Mukohara T, Zejnullahu K, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 2006;116:2695-706.
11. Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006;66:5542-8.
12. Zhang J, Kalyankrishna S, Wislez M, et al. SRCfamily kinases are activatedin non-small cell lung cancer andpro mote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 2007;170:366-76.
13. Gong Y, Somwar R, Politi K, et al. Induction of BIM is essential for apoptosis triggeredby EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 2007;4:e294.
14. Costa DB, Halmos B, Kumar A, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med2007;4:1669-79.
15. Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhancedby BH3 mimetics. PLoS Med 2007;4:1681-9.
16. Deng J, Shimamura T, Perera S, et al. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res 2007;67:11867-75.
17. Choi K, Creighton CJ, Stivers D, Fujimoto N, Kurie JM. Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations. PLoS ONE 2007;2:e1226.
18. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
19. Fujimoto N, Wislez M, Zhang J, et al. High expression of ErbB family members andtheir ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 2005;65:11478-85.
20. Baba I, Shirasawa S, Iwamoto R, et al. Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activatedK i-Ras signaling pathway in human colon cancer cells. Cancer Res 2000;60:6886-9.
21. Zhou BB, Peyton M, He B, et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 andEGFR pathways in non-small cell lung cancer. Cancer Cell 2006;10:39-50.
22. Jones JT, Akita RW, Sliwkowski MX. Binding specificities andaffinities of egf domains for ErbB receptors. FEBS Lett 1999;447:227-31.
23. Shelly M, Pinkas-Kramarski R, Guarino BC, et al. Epiregulin is a potent pan-ErbB ligandthat preferentially activates heterodimeric receptor complexes. J Biol Chem 1998;273:10496-505.
24. Ridley SH, Dean JL, Sarsfield SJ, Brook M, Clark AR, Saklatvala J. A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase- 2 mRNA. FEBS Lett 1998;439:75-80.
25. Rousseau S, Morrice N, Peggie M, Campbell DG, Gaestel M, Cohen P. Inhibition of SAPK2a/p38 prevents hnRNP A0 phosphorylation by MAPKAP-K2 andits interaction with cytokine mRNAs. EMBO J 2002;21:6505-14.
26. Winzen R, Kracht M, Ritter B, et al. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activatedp rotein kinase 2 andan AU-rich region-targetedmechanism. EMBO J 1999;18:4969-80.
27. Pao W, Miller VA, Politi KA, et al. Acquiredresistance of lung adenocarcinomas to gefitinib or erlotinib is associatedwi th a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
28. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 2005;102: 11011-6.
29. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation andresistance of non-small-cell lung cancer to gefitinib. N Engl J Med2005;352:786-92.
30. Agus DB, Akita RW, Fox WD, et al. Targeting ligand- activated ErbB2 signaling inhibits breast andpr ostate tumor growth. Cancer Cell 2002;2: 127-37.
31. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 2006;12:4441-5s.